Stegsita-50 mg Tablet belongs to the class of dipeptidyl peptidase-4 (DPP-4) inhibitors used in treating type 2 diabetes in adults. Stegsita-50 mg Tablet is prescribed for the condition of type 2 diabetes when diet and exercise alone cannot control their blood sugar levels. It is the first-line therapy for patients with type 2 diabetes that restores the body's response to insulin. Insulin is the hormone that controls sugar levels in your blood. People with type 2 diabetes either do not produce enough insulin, or the insulin produced cannot perform its function in the body (insulin resistance). Middle-aged or older individuals are most likely to suffer from type 2 diabetes, so it is also known as adult-onset diabetes.

Stegsita-50 mg Tablet contains sitagliptin. Stegsita-50 mg Tablet work by blocking the action of DPP-4 (an enzyme which destroys the hormone 'Incretin'). The enzyme 'Incretins' helps produce more insulin only when required and reduces blood sugar produced by the liver when not needed.

Stegsita-50 mg Tablet should be taken with food or an empty stomach. However, it should be taken at the same time of the day each time for the best results. For better advice, your doctor will decide what dose should be taken, which can change quickly depending on your condition. The most common side effect of Stegsita-50 mg Tablet is hypoglycaemia (low blood glucose levels), upper respiratory tract infection, nasopharyngitis (infection of the nose and throat with common cold) and headache.

Stegsita-50 mg Tablet should not be used in patients with type 1 diabetes and for treating diabetic ketoacidosis. Stegsita-50 mg Tablet should not be stopped even if you feel better without consulting your doctor as the sugar levels change. If you stop taking Stegsita-50 mg Tablet abruptly, it may increase your sugar levels which could further increase the risk of eyesight loss (retinopathy), kidney (nephropathy) and nerve damage (neuropathy). Stegsita-50 mg Tablet should not be taken if you have severe kidney or liver disease. Please inform your doctor if you have any heart disease or planning to get pregnant or breastfeed. Prolonged intake of Stegsita-50 mg Tablet may cause acute pancreatitis (swollen pancreas) and critical kidney problem. Increased risk of hypoglycaemia (low blood sugar level) can occur when Stegsita-50 mg Tablet is added to other anti-diabetic agents or insulin therapy. In this case, your doctor may adjust the dose of Stegsita-50 mg Tablet. Severe allergic reactions might occur in some patients taking Stegsita-50 mg Tablet like anaphylaxis, angioedema (swelling under the skin), and exfoliative skin conditions, including Stevens-Johnson syndrome. The safety and efficacy of Stegsita-50 mg Tablet in children under 18 years have not been established, so it should not be given to them. Patients taking digoxin (a heart medicine) with Stegsita-50 mg Tablet should be closely monitored as severe drug interaction has been observed.

Stegsita-50 mg Tablet work by blocking the action of DPP-4 (an enzyme which destroys the hormone ‘Incretin’). The enzyme ‘Incretins’ helps produce more insulin only when required and reduces blood sugar produced by the liver when not needed. Thus, Stegsita-50 mg Tablet plays a vital role in controlling blood sugar levels and prevents serious complications of diabetes like eyesight loss (retinopathy), kidney (nephropathy), nerve damage (neuropathy), diabetic foot ulcer and delayed wound healing.

Tell your doctor before consuming Stegsita-50 mg Tablet if you have allergic reactions to sitagliptin, any medications, foods, or any components present in Stegsita-50 mg Tablet. Prolonged intake of Stegsita-50 mg Tablet may cause acute pancreatitis (swollen pancreas) and critical kidney problem. Increased risk of hypoglycaemia (low blood sugar level) can occur when Stegsita-50 mg Tablet is added to other anti-diabetic agents or insulin therapy. In this case, your doctor may adjust the dose of Stegsita-50 mg Tablet. Severe allergic reactions might occur in some patients taking Stegsita-50 mg Tablet like anaphylaxis, angioedema (swelling under the skin), and exfoliative skin conditions, including Stevens-Johnson syndrome. The safety and efficacy of Stegsita-50 mg Tablet in children under 18 years have not been established, so it should not be given to them. Patients taking digoxin (a heart medicine) with Stegsita-50 mg Tablet should be closely monitored as severe drug interaction has been observed.